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Abstract: The poor aqueous solubility of new and existing drug compounds represents a significant
challenge in pharmaceutical development, with numerous strategies currently being pursued to
address this issue. Amorphous solids lack the repeating array of atoms in the structure and present
greater free energy than their crystalline counterparts, which in turn enhances the solubility of the
compound. The loading of drug compounds into porous materials has been described as a promising
approach for the stabilisation of the amorphous state but is dependent on many factors, including
pore size and surface chemistry of the substrate material. This review looks at the applications of
mesoporous materials in the confinement of pharmaceutical compounds to increase their dissolution
rate or modify their release and the influence of varying pore size to crystallise metastable polymorphs.
We focus our attention on mesoporous silicon, due to the ability of its surface to be easily modified,
enabling it to be stabilised and functionalised for the loading of various drug compounds. The use of
neutron and synchrotron X-ray to examine compounds and the mesoporous materials in which they
are confined is also discussed, moving away from the conventional analysis methods.
Keywords: crystallisation; porous silicon; drug confinement; drug delivery
1. Introduction
1.1. Drug Crystallisation and Amorphisation
Nearly half of all the newly developed compounds entering the drug development pipeline suffer
from unfavourable physicochemical properties which affect their bioavailability and, consequently, the
efficacy of the treatment [1]. Poor aqueous solubility is one of the most prevalent issues affecting both
the drug’s pharmaceutical processability and biodistribution and is intimately tied to the compound’s
solid-state properties. The solid phase can be subcategorised into two divisions according to their
order of molecular packing/arrangement: the crystalline and amorphous states.
Crystalline materials are ordered in a repeating pattern, creating a three-dimensional crystal
structure held together by intermolecular forces, including hydrogen bonding and van der Waals
forces. The smallest repeating unit is known as the unit cell and, when built up, shows the composition
of the crystal (Figure 1). Crystalline materials are at their most stable state with atoms packed in
a way that reduces their total potential energy [2]. Due to their high stability, a large amount of
energy is needed to break the intermolecular forces in the crystal structure. When crystalline solids are
melted, they produce a well-defined melting point, determining the energy needed to break down the
crystal structure.
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Figure 1. Three-dimensional structure of the sodium chloride crystal. Each sodium ion is 
octahedrally surrounded by six chloride ions, and each chloride ion is octahedrally 
surrounded by six sodium ions. 
Crystallisation is a process that allows for the formation and purification of many active 
pharmaceutical ingredients (APIs), generating solid particles with the desired morphology, crystal 
form and purity, crucial for controlling a compound’s physicochemical properties. The process can 
be divided into two subprocesses: nucleation and crystal growth. Nucleation is defined as the 
formation of small “crystalline entities”, nuclei, from a supersaturated solution [3,4]. The critical 
nucleus size is said to fall within the range of 100 to 1000 atoms, and once reached, crystal growth 
can follow with the growth of nuclei into “macroscopic crystals” [5]. Nucleation can be classified as 
primary, occurring in the absence of crystalline material, or secondary, which occurs in its presence 
and often serves as a catalyst for further nucleation. Primary nucleation can be classified as either 
homogeneous or heterogeneous. Heterogeneous nucleation occurs at the interface of a surface, 
whereas homogeneous nucleation occurs in a clear solution [6].  
The crystalline state can be composed of multiple components, e.g., co-crystals, solvates and 
hydrates, or a single component, polymorphs. Polymorphism is the ability of a compound to exist in 
more than one crystalline form, with molecules arranging themselves differently within the crystal 
structure, attributing to different physical and mechanical properties between forms. Polymorphs of 
the same material can exhibit different melting points, crystal habits and solubilities, which is of great 
interest and concern to the pharmaceutical industry. Solubility differences between polymorphs can 
be explained by the difference in lattice energy, i.e., the attractive forces that hold the crystal structure 
together and repulsive forces that allow the crystal to dissociate in solution. It is understood that 
metastable polymorphs display greater solubility but can undergo solvent-mediated transformation 
to a more stable, hence lower, solubility state in order to retain system equilibrium [7]. Unfortunately, 
due to the nature of metastable polymorphs, pharmaceutical formulations often contain the most 
stable form. Understanding the factors that play a role in polymorphism is important, with screening 
of crystalline materials playing a fundamental role in drug development. During solution 
crystallisation, the metastable polymorph should crystallise first, according to Ostwald’s rule of 
stages, with subsequent transformation to the stable form [8]. 
Conversely, amorphous materials lack the long-range order that crystalline materials possess. 
The irregular arrangement of molecules leads to unequal intermolecular forces and, hence, physical 
instability in comparison to their crystalline counterparts. Amorphous compounds possess a greater 
Gibbs free energy than their crystalline state and are thermodynamically unfavourable, which can 
lead to their transformation to the stable crystalline state [9]. This instability is advantageous in terms 
of increased solubility of compounds and, hence, bioavailability. A higher energy state often increases 
the mobility of the molecules, giving the compound a greater solubility. However, it is difficult to 
determine the solubility of amorphous compounds due to their tendency to recrystallise upon contact 
with an aqueous environment [10]. 
  
Figure 1. Three-dimensional structure of the sodium chloride crystal. Each sodium ion is octahedrally
surrounded by six chloride ions, and each chloride ion is octahedrally surrounded by six sodium ions.
Crystallisation is a process that allows for the formation and purification of many active
pharmaceutical ingredients (APIs), generating solid particles with the desired morphology, crystal
form and purity, crucial for controlling a compound’s physicochemical properties. The process can be
divided into two subprocesses: nucleation and crystal growth. Nucleation is defined as the formation
of small “crystalline entities”, nuclei, from a supersaturated solution [3,4]. The critical nucleus size is
said to fall within the range of 100 to 1000 atoms, and once reached, crystal growth can follow with the
growth of nuclei into “macroscopic crystals” [5]. Nucleation can be classified as primary, occurring
in the absence of crystalline material, or secondary, which occurs in its presence and often serves
as a catalyst for further nucleation. Primary nucleation can be classified as either homogeneous or
heterogeneous. Heterogeneous nucleation occurs at the interface of a surface, whereas homogeneous
nucleation occurs in a clear solution [6].
The crystalline state can be composed of multiple components, e.g., co-crystals, solvates and
hydrates, or a single component, polymorphs. Polymorphism is the ability of a compound to exist in
more than one crystalline form, with molecules arranging themselves differently within the crystal
structure, attributing to different physical and mechanical properties between forms. Polymorphs of
the same material can exhibit different melting points, crystal habits and solubilities, which is of great
interest and concern to the pharmaceutical industry. Solubility differences between polymorphs can be
explained by the difference in lattice energy, i.e., the attractive forces that hold the crystal structure
together and repulsive forces that allow the crystal to dissociate in solution. It is understood that
metastable polymorphs display greater solubility but can undergo solvent-mediated transformation to a
more stable, hence lower, solubility state in order to retain system equilibrium [7]. Unfortunately, due to
the nature of metastable polymorphs, pharmaceutical formulations often contain the most stable form.
Understanding the factors that play a role in polymorphism is important, with screening of crystalline
materials playing a fundamental role in drug development. During solution crystallisation, the
metastable polymorph should crystallise first, according to Ostwald’s rule of stages, with subsequent
transformation to the stable form [8].
Conversely, amorphous materials lack the long-range order that crystalline materials possess.
The irregular arrangement of molecules leads to unequal intermolecular forces and, hence, physical
instability in comparison to their crystalline counterparts. Amorphous compounds possess a greater
Gibbs free energy than their crystalline state and are thermodynamically unfavourable, which can lead
to their transformation to the stable crystalline state [9]. This instability is advantageous in terms of
increased solubility of compounds and, hence, bioavailability. A higher energy state often increases
the mobility of the molecules, giving the compound a greater solubility. However, it is difficult to
determine the solubility of amorphous compounds due to their tendency to recrystallise upon contact
with an aqueous environment [10].
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1.2. Drug Confinement into Porous Substrates
As mentioned, amorphous compounds display greater solubility than their stable crystalline
counterparts due to higher free energy and greater molecular mobility. Nonetheless, their tendency to
recrystallise can eliminate this highly desirable property [11]. The vast majority of new and existing
drug compounds are crystalline, with their long-range order promoting stability. When confined
in pores, however, they tend to lose their long-range order, remaining in a disordered state, thus
reducing their thermodynamic stability and improving dissolution from the substrate in aqueous
environments [12,13]. Inorganic mesoporous substrates, i.e., materials with pores ranging between 2
and 50 nm in diameter, have shown promise for stabilising drugs in the amorphous state due to their
exceptional properties, such as a large pore volume, which confers the ability to host large amounts
of drug compounds; a high surface area, allowing great potential for drug adsorption; and tuneable
pore size with an uniform distribution, allowing a reproducible loading and release of drugs [14–17].
The amorphisation of pore-loaded compounds is hypothesised to be related, amongst other properties,
with the limited space available within a pore, which can prevent nucleation and subsequent crystal
growth by decreasing Gibbs free energy, leading to the confinement and stabilisation of the drug [18–20].
The confinement of drug compounds inside the pores of mesoporous materials additionally enables
the attainment of local high-drug concentrations and even drug supersaturation, leading to an increase
in drug permeation and subsequent net absorption [21,22]. This has allowed drug confinement into
mesoporous materials to emerge as an attractive strategy to improve the dissolution behaviour of
poorly water-soluble compounds. Thus, understanding the crystallisation (or lack of) behaviour of
drug compounds confined within these substrates at a molecular level is of critical importance in the
formulation of amorphous systems [23,24].
The polymorphism of crystalline compounds has been investigated with the aid of porous
substrates with a view to manipulating the nucleation process [25,26]. As mentioned, crystallisation in
pores can be regulated by changing the pore size to dimensions close to that of the critical nucleus
size, therefore regulating polymorphism if each form has a different critical nucleus size. It has also
been stated that pore sizes should be approximately 20 times the molecular radius of the compound
for crystallisation to occur in confinement [27]. Dwyer and collaborators referred to this finding
when discussing the results of fenofibrate confined in nanoporous silica. Amorphous fenofibrate was
discovered in pores less than 20 nm, but crystalline in pore sizes greater than 20 nm [28]. According to
the molecular radius of fenofibrate (~1.27 nm), the drug would not have enough space in the 20 nm pore
to crystallise and would therefore be amorphous. The large surface area of the porous substrate could
also regulate crystallisation by providing a surface for heterogeneous nucleation on the pore walls.
The polymorphism of anthranilic acid (AA), for example, known to exhibit three polymorphs,
was investigated using porous and nonporous glass as crystallisation templates. Form I was mixed
with nonporous glass beads and controlled pore glass (CPG) and heated above the melting point of
the acid. Form III, the metastable polymorph known to crystallise from the melt, was discovered on
the surface of the nonporous glass and confined within a controlled pore glass of 55 nm. Form II was
dominant in pores of 7.5 nm, with the nanoscale crystals depicted by the decrease in melting point of
anthranilic acid and broadening of the X-ray diffraction (XRD) peaks (Figure 2). Confinement led to
the stabilisation of the metastable polymorph, with storage studies conducted for one month at room
temperature. The authors suggested that the confinement of metastable Form II was due to the critical
nucleus size being suitable for the smaller pore sizes but could also have been due to the influence of
pore size on heterogeneous nucleation [25].
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Figure 2. (a) X-ray powder diffraction (XRPD) data for anthranilic acid crystallised by 
cooling of its melt on nonporous glass beads and within controlled pore glasses (CPGs) of 
various pore sizes. (b) Structure of anthranilic acid (AA). Reproduced with permission from 
[25]. 
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polymorphs and limited aqueous solubility. Nartowski and collaborators investigated the influence 
of pore size and drug-loading method on the polymorphism of indomethacin. The CPG and 
mesoscopic cellular foam (MCF) were used as the substrates due to their varying pore sizes. Loading 
from the melt led to the identification of amorphous indomethacin within the porous materials, 
displaying an amorphous “halo” in the X-ray powder diffraction (XRPD) patterns. Solid-state nuclear 
magnetic resonance (NMR) was also utilised, with the broadening of indomethacin peaks in the 
spectra indicating the many orientations of carbon atoms and differences in environments within the 
amorphous sample. The smaller pore size of MCF prevented the thermally induced recrystallisation 
of indomethacin; however, the larger pore size of CPG allowed thermally induced recrystallisation 
at higher concentrations. This highlights the importance of drug concentration when loading the 
porous material, as well as pore dimensions [29]. The addition of solvent to the melt-loaded MCF 
caused molecular rearrangement in indomethacin, driving the drug’s transition from amorphous to 
crystalline. Increased drug-loading was observed with the increase in total pore volume and surface 
area. After the addition of methanol to the loaded CPG, the crystallisation of multiple polymorphs 
was identified, with the addition recrystallising pure form V from the amorphous state, usually 
produced from the desolvation of the methanol-indomethacin solvate. 
The influence of pore volume and surface area on drug-loading capacity was also investigated 
by Bavnhøj and collaborators using three model drugs with good glass-forming capabilities [18]. 
Loading capacity was defined to be either monomolecular loading capacity (MLC) or pore-filling 
capacity (PFC), and differential scanning calorimetry (DSC) was used to determine the MLC defining 
the heat capacity over the glass transition temperature from the amorphous state of each drug. Pore 
volume was determined to be the limiting factor to drug-loading capacity in this case. Increase in 
surface area from 550 m2/g to 681 m2/g did not increase the experimental MLC value, as greater 
surface area was produced at the expense of pore size, leading to spatial limitation. The theoretical 
MLC suggested the general trend to be an increase in MLC with an increase in surface area, which 
assumed the entire silica surface to be covered by drug molecules and did not account for the blocking 
Figure 2. (a) X-ray powder diffraction (XRPD) data for anthranilic acid c ystallised by ooling of its
melt on onporous glass beads and within controlled pore glasses (CPGs) of various por sizes. (b
Structure of anthranilic acid (AA). Reproduced with permission from [25].
Among pharmaceutically relevant compounds, indomethacin has been extensively employed
as a model drug when investigating the influence of confinement on drug molecules, due to its
array of polymorphs and limited aqueous solubility. Nartowski and collaborators investigated the
influence of pore size and drug-loading method on the polymorphism of indomethacin. The CPG
and mesoscopic cellular foam (MCF) were used as the substrates due to their varying pore sizes.
Loading from the melt led to the identification of amorphous indomethacin within the porous materials,
displaying an amorphous “halo” in the X-ray powder diffraction (XRPD) patterns. Solid-state nuclear
magnetic resonance (NMR) was also utilised, with the broadening of indomethacin peaks in the
spectra indicating the many orientations of carbon atoms and differences in environments within the
amorphous sample. The smaller pore size of MCF prevented the thermally induced recrystallisation
of indomethacin; however, the larger pore size of CPG allowed thermally induced recrystallisation
at higher concentrations. This highlights the importance of drug concentration when loading the
porous material, as well as pore dimensions [29]. The addition of solvent to the melt-loaded MCF
caused molecular rearrangement in indomethacin, driving the drug’s transition from amorphous to
crystalline. Increased drug-loading was observed with the increase in total pore volume and surface
area. After the addition of methanol to the loaded CPG, the crystallisation of multiple polymorphs was
identified, with the addition recrystallising pure form V from the amorphous state, usually produced
from the desolvation of the methanol-indomethacin solvate.
The influence of pore volume and surface area on drug-loading capacity was also investigated
by Bavnhøj and collaborators using three model drugs with good glass-forming capabilities [18].
Loading capacity was defined to be either monomolecular loading capacity (MLC) or pore-filling
capacity (PFC), and differential scanning calorimetry (DSC) was used to determine the MLC defining
the heat capacity over the glass transition temperature from the amorphous state of each drug.
Pore volume was determined to be the limiting factor to drug-loading capacity in this case. Increase in
surface area from 550 m2/g to 681 m2/g did not increase the experimental MLC value, as greater surface
area was produced at the expense of pore size, leading to spatial limitation. The theoretical MLC
suggested the general trend to be an increase in MLC with an increase in surface area, which assumed
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the entire silica surface to be covered by drug molecules and did not account for the blocking of pores
due the molecular size of the drugs. By plotting the experimental MLC along with the theoretical
MLC and PFC as a function of surface area and pore volume, the authors were able to identify their
influence on drug-loading fraction, with four zones describing loading within the pores or on the
surface of the mesoporous silica, which could prove beneficial to future investigations looking into
compound-loading onto mesoporous materials.
1.3. Crystallisation Characterisation Techniques
Thermal evaluation of the effect of confinement on drug compounds can be provided by DSC,
whilst also offering fast benchtop analysis. This technique can be used to quantify and differentiate
between drug molecules confined in porous materials and that on the surface of the material [30]. It can
also differentiate between crystalline and amorphous material. Kiwilsza and collaborators used DSC
to determine the surface crystallisation of nimodipine in porous silica [17]. The endotherm indicated
the melting of crystalline nimodipine on the surface of the porous silica when unwashed. Washing the
loaded silica removed the surface crystalline material, which was indicated by the lack of endotherm.
As no melting peak was observed for the washed samples, it was inferred that the confined nimodipine
was amorphous. To confirm that the washed particles were loaded with nimodipine, the authors
carried out a drug dissolution study. More than 60% of the drug was reported to dissolve and be
released within the first three minutes of the study. Dwyer and collaborators took a similar approach,
using DSC in the analysis of confined fenofibrate [28]. The sharp single melting endotherm indicated
crystalline fenofibrate, but the lack of melting point for the smallest pore size indicated amorphous
fenofibrate, which was confirmed by NMR. Double peaks in the DSC thermograph would speculate
surface crystallisation in addition to confined crystals.
The XRPD offers a complementary way of assessing the crystallinity of confined
compounds [19,25,28,29,31–33]. Like DSC, XRPD can be used to determine if the confined drug
is in its crystalline or amorphous state. If the drug is crystalline, diffraction peaks will be observed
in the pattern, and if well-defined, they can be used to determine the crystal structure present using
crystallographic software. It can also illustrate if a mixture of crystal systems are present when dealing
with polymorphs [31]. One of the disadvantages of XRPD is the decrease in peak intensity at greater
angles. A way to overcome this is through neutron powder diffraction, which relies on the same
principles as XRPD. Whilst X-rays interact with the electrons in the sample, neutrons interact with
the nuclei. This means that neutron diffraction is better at resolving the hydrogen positions of a drug
compound, for example, or can be used to investigate surface interactions between the drug and the
pores it is confined within. Unfortunately, powder neutron diffraction requires the drug compounds to
be deuterated, where the hydrogen atoms are replaced with the isotope deuterium, which may not
always be technically feasible. Analysis by neutron can only be carried out in specialised research
facilities: for example, ISIS Neutron and Muon Source in the UK and the Institut Laue-Langevin located
in France.
Aside from DSC and XRPD methods, neutrons and synchrotron X-rays have shown promise
as techniques used to investigate porous substrates. Webber and Dore used neutron diffraction
cryoporometry to assess the crystallisation behaviour of water and ice in porous silica. They were
able to differentiate between the different states, observing that the signal produced was proportional
to the quantity of the liquid or solid crystalline state, hence, were able to track the ratio as a
function of temperature. From this, the Gibbs-Thomson equation could be applied to interpret
structural information of the compound’s state when confined in SBA-15, a type of mesoporous silica
nanoparticle [34].
The confinement of proteins in mesoporous silica was also investigated using small-angle neutron
scattering (SANS), assessing their arrangement within the pores. Again SBA-15 was chosen for its
well-defined geometrical pores, and KIT-6 mesoporous silica was chosen for the contorted nature of
the pores, allowing for the comparison of protein arrangement with regards to pore morphology [35].
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The authors first charged the proteins to allow for electrostatic attraction with the silica substrates.
They then observed that lower protein concentrations showed lower signal amplitudes from additional
protein adsorbed on the walls of the silica matrix or free inside the pores, which distorted the scattering
and, hence, substantiated that the information produced from SANS was reliable. Further research
detailed the use of deep inelastic neutron scattering (DINS) to investigate mesoporous silica, due to its
sensitivity for the investigation of the local environment of protons, complementing diffraction studies
on atomic spatial distributions [36]. Water molecules were confined within hexagonally arranged
porous silica with pore sizes of 4.3 nm. This led to the conclusion that hydrogen bonding between the
water molecules and the silanol groups was much stronger than the hydrogen bonds within unconfined
water, supporting the hypothesis of a difference in proton environment.
Pair distribution function (PDF) has also been used to probe the local atomic ordering of SBA-15
porous silica by investigating the relationship between porous structure and thermal stability of the
substrate. Atomic pair distribution is the sine Fourier transform of the structure function that is
determined experimentally by X-ray or neutron diffraction and can be used to study materials at an
atomic scale [37]. Rantanen and collaborators used small-angle X-ray diffraction (SAX) to determine
the distance between the pores and, hence, the pore wall thickness. The SAX diffraction data further
showed that, with decreasing pore size, the position of the (100) peak of silica shifted to a lower 2θ.
Decrease in pore size also showed an increase in wall thickness and a lower order of structure possessed
by the walls. The measured structure function showed differences between pore sizes, with greater
separation between peaks for the samples with larger pore sizes (9.69 and 12.05 nm average diameter),
suggesting that the ordering of SiO4 tetrahedra was more regular. There was also an indication that
silicon atom pairs were separated by a lesser distance, causing the structure to be more tightly packed,
resulting in a greater density at the pore walls, which could influence the stability of the porous
structure as a whole [37]. The PDF analysis has also been used to investigate the changes in short- to
medium-range structures of nanoporous silica, characterising pore morphology as well as pore wall
thickness and atomic structure within the pore walls [37,38].
Detailed structural information can also be gained from using X-ray total scattering coupled
to atomic PDF and solid-state NMR. Atomic PDF is well-suited for structural characterisation of
crystalline materials, as well as nano-sized and amorphous materials. It has been stated that PDF
is a representation of “total scattered X-ray intensities and reflects both long-range atomic structure,
manifested in the sharp Bragg peaks, and the local structural imperfections, manifested in the diffuse
components of the total scattering pattern” [39]. The structural information that PDF provides
persists over long distances and can therefore describe structural properties at varying orders of scale.
However, structural studies based on PDFs obtained from total X-ray scattering data of amorphous
organic-inorganic nanocomposites can prove challenging due to their weak scattering power.
An application of such principles was explored by Hsieh and collaborators, where they investigated
mononitrosyl complexes in porous silica matrices to determine a structural characterisation strategy
to apply to another compound, sodium nitroprusside. As with any investigation, complementary
methods of analysis are needed, and in this study, short-range NMR and long-range XRD provided the
orthogonal approach. Thus, PDF can be used to bridge the gap between the two methods. The XRD
data of loaded and unloaded silica showed amorphous features within the diffraction patterns with
a characteristic peak at Q ~1.64 Å. Change in scattering contrast was witnessed between unloaded
and loaded samples, with the principal peak within the loaded diffraction pattern displaying a
broader nature with a lower intensity [39]. In a study by Nartowski and collaborators, 19F solid-state
NMR together with terahertz spectroscopy was used to detect the presence of confined molecules of
flufenamic acid (FFA) in different environments and motional regimes [40]. This enabled the authors
to gain in situ mechanistic insight into the molecular self-assembly at different length scales by taking
advantage of the higher sensitivity of 19F nuclei to changes in the local environments of molecules
confined in the porous hosts. The authors reported for the first time the presence of a liquid-like layer
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of drug molecules on the porous scaffold’s surface, which affected the nucleation and crystallisation
behaviour of the drug (Figure 3).P armace tics 2020, 12, x 7 of 24 
 
 
Figure 3. (A) Structure of flufenamic acid (FFA) with labelling of the carbon atoms. (B) 
Average dimensions of the FFA molecule and the three different states of FFA species inside 
the pores. (C,D) Different mechanisms for FFA adsorption and stabilisation of the 
amorphous state. (E) Mechanism of the formation of crystalline FFA form I in mesoscopic 
cellular foam (MCF). Reproduced with permission from [40]. 
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characteristics of a hydrogel composed of bacterial cellulose and acrylic acid, with high diffusion 
times indicating the interconnected nature of hydrogel pores [41]. NMR relaxation times have also 
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proton spins near the pore’s surface is faster than in the bulk, providing a difference which can be 
measured. Sørland and collaborators used NMR to investigate pore size distribution of porous rocks, 
further concluding that NMR was more sensitive to pore size distributions than the mercury intrusion 
technique, as mercury underestimates larger cavities [43].  
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while trying to develop a method for shaping and polishing the surfaces of silicon and germanium 
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Figure 3. (A) Structure of flufenamic acid (FFA) with labelling of the carbon atoms. (B) Average
dimensions of the FFA molecule and the three different states of FFA species inside the pores. (C,D)
Different mechanisms for FFA adsorption and stabilisation of the amorphous state. (E) Mechanism of
the formation of crystalline FFA form I in mesoscopic cellular foam (MCF). Reproduced with permission
from [40].
NMR has also been utilised to characterise the porous structure of hydrogels. Average pore
diameter and pore volume are usually determined using mercury porosimetry and gas adsorption, but
due to the nature of the hydrogel, NMR provides an alternative that is not impeded by the liquid phase.
Low-field NMR—pulsed gradient spin echo was employed to understand the pore characteristics
of a hydrogel composed of bacterial cellulose and acrylic acid, with high diffusion times indicating
the interconnected nature of hydrogel pores [41]. NMR relaxation times have also been used to
determine pore radius distribution profiles of hydrogels quickly without destroying the sample. NMR
measurements rely on the excitation of targeted nuclei spins in the aqueous phase and subsequent
measurement of the proton spins returning to equilibrium [42]. The relaxation rate of proton spins near
the pore’s surface is faster than in the bulk, providing a difference which can be measured. Sørland and
collaborators used NMR to investigate pore size distribution of porous rocks, further concluding that
NMR was more sensitive to pore size distributions than the mercury intrusion technique, as mercury
underestimates larger cavities [43].
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1.4. Porous Silicon
One of the materials that has shown great promise for the confinement of drugs is porous silicon
(pSi). When pores are introduced into the structure of the chemical element silicon, rendering a large
surface-to-volume ratio, we obtain the pSi form. The discovery of pSi was made fortuitously in 1956
while trying to develop a method for shaping and polishing the surfaces of silicon and germanium [44].
At the time, their porous nature was not reported, and only several years later, in 1971, a procedure
conducive to obtaining highly microporous silicon was published [45]. However, it was not until
the early 1990s when Leigh Canham, concurrently with Lehmann and Göselle, hypothesised that
the thin silicon filaments, created when the pores become large and numerous enough to overlap,
might display quantum confinement effects, leading to the demonstration that silicon wafers could
emit light if subjected to chemical and electrochemical dissolution [46,47]. These discoveries soon
instigated a substantial amount of research focused on Si-based lasers, displays, and optoelectronic
switches. Nonetheless, due to the material’s mechanical and chemical instability, as well as its low
electroluminescence efficiency, most of the research in that area subsequently faded. In addition to its
electronic properties, pSi was later found to act as a bioactive material [48], which rekindled its study
for biomedical applications [49–54].
There are over 40 different fabrication routes for pSi, using both “top-down” and bottom-up”
approaches. “Top-down” methods rely on generating voids in monocrystalline silicon wafers using
the chemical and/or physical removal of atoms from the silicon substrate to create highly directional
porosity. “Bottom-up” approaches, on the other hand, depend on assembling silicon clusters together
in a way that, while establishing a crystalline form, leaves voids behind so that a porous structure
can be synthesised [55]. Most processes for obtaining pSi over the last 50 years have relied on
electrochemical anodisation of monocrystalline silicon wafers in aqueous electrolytes comprised of
ethanol and hydrofluoric acid (HF) [56,57]. In electrochemical etching, the solid silicon wafer functions
as an anode, while a platinum (Pt) plate functions as a cathode when both are submerged in the
HF-ethanol electrolyte (Figure 4). The intrinsic properties of the pSi obtained through this route, such
as pore size and shape, pore layer thickness, and porosity, are mainly determined by the manufacturing
conditions. These conditions include current density, wafer type, resistivity, HF concentration, chemical
composition of the electrolytes, crystallographic orientation, temperature, time, electrolyte stirring,
illumination intensity, and wavelength. While complete control over all of these process parameters
is a major challenge for the fabrication of pSi, most of them are somehow related and can be kept
constant, thereby achieving a satisfactory degree of reproducibility during the whole process [58].
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1.5. Porous Silicon Surface Stabilisation
Following anodisation, the pSi surface becomes hydrogen-terminated (Si–Hx) and displays a
certain degree of environmental chemical reactivity. The bonds at the surface can be Si–H, Si–H2, and
Si–H3 hybrids and render the silicon surface prone to oxidation even in dry ambient conditions [57,59,60].
In addition to the native oxidation of pSi, the extent and rate of oxidation is dependent on the storage
conditions, with the transition from hydrophobic hydrogen termination to the hydrophilic oxidised
surface taking place over the course of months at room temperature. Complete native oxidation,
however, occurs over a much longer time period [61,62].
The silicon hydride species present in the as-anodised surface of pSi can promote reactivity towards
any compound potentially loaded within the pores of pSi [63,64], and thus, a stable nonreactive surface is
essential to replace the unstable hydrogen-terminated surface of the freshly etched pSi. The conversion
of the reactive groups at the surface into more stable oxidised, hydrosilylated, or (hydro) carbonised
forms allows for further modification of the pSi surface (Figure 5), which can include radiotracers such
as 18F [65]. Selective substitution of hydrogen on the surface of pSi with hydroxyls can also be conducted
to leverage direct chemical linking of the pSi with organic molecules, therefore circumventing the
intermediate oxide layer. This can be achieved either by: (1) selective oxidation of Si–H groups using
diluted solutions of hydrogen peroxide in water, with the addition of 15% methanol or 10% acetone to
render the solution capable of wetting the hydrogen-terminated surface of pSi and penetrating into the
pore volume, or (2) by direct or indirect substitution of the surface-bound hydrogen with a hydroxyl
via intermediate halogenation of the pSi surface by a radical mechanism and directly as a result of the
nucleophilic substitution of the hydride ion (H–) with a hydroxyl anion from an alkaline solution [66].
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1.5.1. Thermal Oxidation
One of the most straightforward methods to oxidise pSi surfaces is through thermal oxidation,
which gives rise to thermally oxidised pSi (TOpSi) [67,68]. The thermal oxidation of the pSi surface
occurs at a threshold temperature of around 250 ◦C under ambient air conditions where the loss
of hydrogen from the pSi surface is first detected and where the Si dangling bond sites generated
are able to chemisorb O2 dissociatively, leading to the first stage of surface oxidation. This initial
oxidation promotes further insertion of oxygen into the Si–Si back-bonds, giving rise to –OySiHx
species. Concurrently, the oxidation process also leads to the for ati f s rface Si– s ecies as a
result of the oxygen i sertion into the Si–H bonds [69]. The c r i f t ti e SiySiHx surface
to OySiH, Oy i , t er al oxidation has b en amply reported in the literature,
Pharmaceutics 2020, 12, 214 10 of 24
especially due to its effect on pSi photoluminescence [69–71]. In addition to thermal oxidation, there
are various other ways to obtain a pSi surface oxide. These include maintaining the pSi under an
atmosphere of oxygen [69], a short exposure to ozone [72], and treatments with dimethyl sulfoxide [73]
or hot concentrated solutions of hydrogen peroxide [74].
1.5.2. Hydrosilylation
Hydrosilylation is another process of passivating the silicon surface and can summarily be
described as a radical-induced reaction which can be initiated either by free radical initiators, ultraviolet
light (UV), or thermal energy. The latter case produces a covalent linkage of alkyl chains to the
hydrogen-terminated pSi surface, using unsaturated compounds such as terminal alkenes and alkynes
as substrates. The first reports of a covalent linkage of densely packed, long alkyl chains directly to
a silicon surface were published by Linford and Chidsey, where they employed pyrolysis of diacyl
peroxides in the presence of hydrogen-terminated silicon. The authors used the thermal decomposition
of diacyl peroxides to produce alkyl radicals, CH3(CH2)n• via CH3(CH2)nCOO•, which were then
reacted with the silicon surface. They also concluded that a large number of the linkages formed using
this process were C to Si direct bonds. However, it was also noted the presence of some carbonyl
groups, which indicated that these monolayers were not comprised solely of alkyl chains. This was
attributed to the presence of hydrolysable acyloxy bonds to the silicon surface (Si–O–C(O)–CH2–) for
one-third of the chains, whereas the more robust alkyl bonds to the silicon surface (Si–CH2–) comprised
the remaining fraction of the chains [75]. The same group later reported an optimised method for
obtaining chains packed at approximately 90% the density of crystalline n-alkanes using pyrolysis of
mixtures of either 1-alkenes or 1-alkynes and diacyl peroxides [76]. The presence of stable Si–O bonds
at the surface decreases the number of reaction centres, since these bonds cannot be broken by UV light
or by the thermal energies typically used in hydrosilylation reactions. By employing hydrogenated
amorphous silicon (a—Si:H), a material known to be more resistive against oxide formation than
crystalline silicon [77] for the fabrication of hydrosilylated silicon surfaces, the additional benefit
of allowing the substrate to be treated under ambient conditions during surface functionalisation
could be achieved [78]. Lewis acid-mediated hydrosilylation of alkynes and alkenes on nonoxidised
hydride-terminated porous silicon has also been reported, where EtAlCl2 acts upon terminal, cis- and
trans-disubstituted, trisubstituted, and tetrasubstituted alkenes and terminal and internal alkynes to
promote the covalent attachment of organic functionalities to the silicon surface via Si–C bonds, resulting
in alkenyl- or alkyl-terminated surfaces [79–81]. A hydrosilylation approach towards the formation
of Si–C bonds on silicon surfaces, which yielded surface-bound vinyl and alkyl groups, respectively,
has also been described. The authors employed a Pt-catalysed reaction between 3,4,-dichlorobutene
and hydrogen-terminated silicon surfaces, where after an initial step involving adsorption of Pt
on the hydrogen-terminated silicon, an oxidative addition of the SiH to the coordination sphere of
the Pt(0) complex to form (dichlorobutene)3Pt2+ (H)(Si) occurs. Subsequently, hydride addition to
dichlorobutene takes place during the migratory insertion step, which is followed by the reductive
elimination of the alkylsilane [82]. The pSi surface can also be hydrosilylated by reductive electrolysis
of organohalides, where the pSi is immersed in a solution containing an organohalide (RX, X=I, or
Br) and then passing a cathodic current through the solution. The hydrosilylation occurs either by
direct reaction between the Si radical and the alkyl radical or by reduction of the Si radical to an anion,
followed by a nucleophilic attack of the organohalide [83]. This hydrosilylation route has been reported
to functionalise 20%–80% of the Si–H bonds on the pSi surface, which still leaves the remaining Si–H
bonds vulnerable to attack and oxidation. However, by following the organohalide functionalisation
with a CH3I methylation of the remaining Si–H bonds, it is possible to achieve a larger Si–C surface
coverage [84].
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1.5.3. Thermal Carbonisation
Thermal carbonisation is another process employed for stabilising the silicon surface, which also
involves chemical derivatisation of the pSi surface with organic compounds and formation of Si–C
bonds [85]. It was first described in the late 1990s as an attempt to stabilise the photoluminescence of
pSi and, although the treatment does indeed produce a stable nonstoichiometric silicon carbide layer
on the pSi surface, it also completely quenches its initial photoluminescence [86,87]. Early efforts relied
on reactions involving heating of pSi single-crystals, which in turn proved potentially damaging to the
fragile nanoscale structure of the substrate [88]. Several research groups have subsequently investigated
the formation of Si–C bonds on Si at room temperature using one- or two-step methods [79,89–91].
One-step derivatisation reactions in Si usually entail photo- or electrochemical methods to attach one
or two carbon fragments to the surface (CH3–Si and RCO2–Si, R=H, and CH3), whereas in the two-step
method developed by Lewis and collaborators, the H-terminated Si surface was first chlorinated
radically by PCl5 and subsequently quenched with a Grignard reagent [91].
The pSi surface produced via thermal carbonisation is remarkably stable to boiling alkali solutions,
which indicates a sufficient degree of coverage to fully protect the exposed surface, whereas the
Si–H-terminated pSi dissolves quickly under these conditions [89]. Stability studies of differently
stabilised pSi samples have shown that the thermal carbonisation of pSi (TCpSi) is an even more
efficient stabilising method than thermal oxidation [92]. Functionalisation of TCpSi by radical coupling
of sebacic acid has been also reported, as well as their capability to further modify the pSi surface using
standard bioconjugate chemistry methods. The surface was stable and comparable to a non-functional
thermal oxide but superior to the widely used carboxy-terminated surface prepared by the thermal
hydrosilylation route [93].
1.5.4. Thermal Hydrocarbonisation
Thermal decomposition of acetylene is another method that can be used to generate a
hydrocarbon-terminated surface [94]. This surface treatment allows functionalisation to be carried out
at a lower temperature, as there is a threshold temperature which changes the thermal functionalisation
of pSi into carbonisation. This temperature, nonetheless, allows for acetylene to be continuously
circulated without the problem of graphitisation. Below 700 ◦C, the hydrogen atoms remain on the
pSi surface, rendering it hydrophobic (Si–C–H bonds, thermally hydrocarbonised pSi, and THCpSi).
Temperatures above 700 ◦C, on the other hand, allow the dissociation of hydrogen from the surface,
rendering the surface more hydrophilic than the material produced at lower temperatures. One of the
advantages of using small gaseous molecules of acetylene includes the faster and improved diffusion
into the pores, which further improves the efficiency of surface coverage. The hydrocarbon-terminated
surface Si–C–H can be present in several configurations, with three silicon atoms bonded to a C atom
presenting as the most common. This surface treatment has several advantages over the carbonisation
treatment, including: the pSi surface remaining hydrophobic, the treated layer is thinner, and the gas
adsorption properties are different from those found in the carbonised pSi. This treatment also enables
further functionalisation of the pSi for cell-targeting and antifouling purposes [95,96].
1.6. Metalothermic Reduction
Other than etching, chemical conversion of silica is nowadays one of the most prevalent routes for
obtaining pSi [97]. Nanostructured silica can be reduced to pSi with the assistance of reducing agents
such as magnesium and aluminium at moderate temperatures (400–800 ◦C). The milder reduction
temperatures offer a desirable alternative for producing silicon when compared with the industrial
blast furnace carbothermic reduction method (over 1400 ◦C) [98]. Magnesiothermic reduction of silica
was first described in the early 1980s in India when researchers tried to obtain solar-grade silicon
from rice husks [99,100]. The process of magnesiothermic reduction can be briefly detailed as follows:
starting at a temperature of 400-600 ◦C in an inert atmosphere or vacuum, magnesium gas reacts with
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silicon dioxide to yield silicon and magnesium oxide according to the chemical reaction depicted in
Equation (1):
SiO2 (s) + 2 Mg (g)→ Si(s) + 2 MgO (s) (1)
The magnesia (MgO) can be easily removed afterwards with HCl, leaving behind a silicon replica
with higher surface area than the starting template. The exothermic nature of the reduction reaction
allows for utilisation of the heat produced, aiding the process further and lowering the cost of the
reaction [101].
It is, however, noteworthy to point out that a side reaction can reduce the yield of silicon through
the formation of magnesium silicide (Mg2Si), as depicted in Equation (2). The Mg2Si is obtained
when the gaseous magnesium reacts with silica on the surface, and, consequently, the formed Si
product prevents access of magnesium to silica in the interior, causing a mismatch of the stoichiometric
ratio of magnesium and silica, thus resulting in an undesired side reaction that produces magnesium
silicide [102]. The formation of Mg2Si reduces the yield of Si formed and impacts on the morphology
of the final product upon removal, which occurs concurrently with the MgO removal with the HCl
wash [103].
Si (s) + 2Mg (g)→Mg2Si(s) (2)
The greatest advantages of the magnesiothermic reduction of silica is the inexpensive silica
feedstocks that can be employed (sand, rice husk ash, etc.), as well as the lower required amounts of
HF or organic solvents throughout the process. Another reducing agent that has been given increasing
attention is aluminium. Aluminium is an inexpensive metal which has long been known to react
rapidly with silica to yield silicon, according to Equation (3).
3SiO2(s) + 4Al(l)→ 3Si(s) + 2Al2O3(s) (3)
The advantages of using aluminium, besides its lower cost compared with magnesium, are
the avoidance of minor silicide by-products (such as the Mg2Si described earlier) and the alumina
passivation of the silicon structure [104].
The magnesiothermic reduction of silica nanoparticles has been reported to increase the surface
area from 8.2 m2g−1 to 386 m2g−1 after a 12-h reaction time at 500 ◦C. Pore volume also increased
from 0.07 cm3g−1 to 1.7 cm3g−1. The surface area of silicon particles produced by aluminothermic
reduction was a magnitude smaller than the magnesium-reduced product, with the greatest surface
area reported as 37 m2g−1 after 24 h at 650 ◦C. Pore volume was determined to be 0.51 cm3g−1 after 12
h at 650 ◦C. Transmission electron microscopy (TEM) images of the porous substrate showed that a
aluminothermic reduction produces a less porous substrate than magnesiothermic reduction, with the
porous silicon composed of layers [105].
1.7. Drug Loading and Release from pSi
As mentioned previously, there are many advantages of confining pharmaceutical compounds into
mesoporous materials. To leverage this in the case of pSi, drugs need to be loaded into a mesoporous
matrix in a reproducible fashion and in high yield. The most common methods for drug loading in the
context of pSi materials are solvent loading, where the mesoporous matrix is immersed into a saturated
solution of the drug [106–108], melt intrusion, where the mesoporous matrix is put into contact with
the molten drug substance which facilitates complete pore-filling through capillary action [109], or
even by supercritical drying of ultrahigh porosity (90%) pSi [110]. When assessing the degree of
drug loading, it is critical to distinguish the fraction of drug within the pores from the drug on the
external surface of the material. Several methods have been employed to quantify drug loading,
such as calorimetry [30,111], high-performance liquid chromatography (HPLC) [107,108], atomic force
microscopy (AFM) together with Time-of-Flight Secondary Ion Mass Spectroscopy (ToF-SIMS) [112],
gas sorption [64], and XRPD. While there is not a single method that could discern between loaded
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and surface-bound drugs in pSi, a suite of thermoanalytical and spectroscopic techniques has been
proved to provide valuable information on the physical state of the drug molecules.
As previously mentioned, surface modification of pSi makes the substrate adaptable for the
confinement of many compounds, both hydrophilic and hydrophobic. Loading capacity can increase if
the pore surface is tailored to suit the functional groups of the loaded molecule. It has been reported
that hydrophobic drugs load better into hydrophobic pores, but the drugs could prove difficult to
wet in physiological conditions [113]. To try and address this, a three-step pSi functionalisation
method was employed. Firstly, the pSi films were hydrosilylated with 1-dodecene, followed by etching
of the surface and a further hydrosilylation stage using (3-aminopropyl)triethoxysilane (APTES).
This process provided the outer surface with hydrophilic functional groups and the inner pore surfaces
with hydrophobic groups, which suited the hydrophobic drug camptothecin. An additional layer of
polymer was attached to the loaded pSi surface to further control the release of the drug. Modification
of the pSi doubled the drug-loading concentration, and the external polymer coat improved the drug
release profile with a slower, steadier release than the control (Figure 6) [114].
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surfaces of pSi films to allow improved camptothecin (CPT) drug loading and release and CPT release
profiles from (a) pSi-ozone-APTES, (b) pSi-dodecene-air plasma-APTES, and (c) pSi-dodecene-air
plasma-APTES-2 wt% poly(HPAm-co-BPAm). Reproduced with permission from [114].
Nanoparticles of pSi have also been employed for drug delivery using polymer coatings, forming
porous silicon-polymer composites. Krepker and Segal detailed the many designs of pSi-polymer
composites and their fabrication, endowing the surface of the pSi with a wide range of surface
chemistries for a variety of applications [115]. Porous silicon polymer nanocomposites have been used
for the delivery of peptide nucleic acids (PNA) due to their large loading capacities [116]. However, pSi
alone does not allow the release of the nucleic acid from the endo-lysomal vesicles into the cytoplasm
and, therefore, requires additional modifications. Oxidised pSi nanoparticles were loaded with PNA
before the application of a polymer coating, poly((ethylene glycol)–block–(2-(dimethylamino)ethyl
methacrylate–co–butyl methacrylate)) (PEGDB). The PEGDB allowed for the systemic delivery of
negatively charged nucleic acids, facilitating endosomal release of the nucleic acid [117]. The modified
surface of the pSi nanoparticles led to increased stability and reduction in particle aggregation in
comparison to the uncoated pSi nanoparticles. It was stated that the increased stability witnessed
was due to the polymer-blocking surface adsorption of proteins and ions, therefore preventing
aggregation [118].
Salonen and collaborators looked at ibuprofen confined within thermally carbonised pSi to
assess the loaded drug in comparison to drug crystallised on the surface by DSC [30]. Ibuprofen
loaded onto nonporous silicon showed a melting peak (endotherm) at 74 ◦C, close to that of the bulk
drug (76 ◦C). Ibuprofen loaded in pSi and washed in a solution of water and ethanol displayed two
endotherms in the thermograph: the suppressed melting point of confined crystalline material and
a small amount of surface crystals with a melting peak close to that of bulk ibuprofen. Washing
the loaded pSi in pure ethanol showed no surface crystallisation. Depression of the melting point
Pharmaceutics 2020, 12, 214 14 of 24
is often observed for confined crystalline compounds due to the reduced size of the crystals [119].
The confinement and increased drug dissolution has been further confirmed with studies which
included the poorly water-soluble drugs indomethacin and griseofulvin, with the amorphous state of
the confined compounds enhancing the drug dissolution or drug permeation rate [19,107,120–122].
In these studies, the loading degree of both drugs ranged between 6 to 29 wt% for indomethacin
and 6 to 17 wt% for griseofulvin, depending on surface chemistry and pore size of the pSi substrate
and highlighted the potential impact of these physicochemical parameters in further pharmaceutical
processing. The loading of poorly water-soluble antiviral compounds, such as saliphenylhalamide, has
also been conducted, in which a 2.88% drug loading was reported [108]. The authors attributed the
low loading values to the drug’s partition coefficient (a measure of the lipophilicity of a compound)
and its molecular radius.
The application of pSi to deliver the anti-cancer drug doxorubicin to transferrin
receptor-overexpressing tumour cells across a blood-brain barrier (BBB) model has also been
reported [123]. The pSi particles were first functionalised using undecylenic acid to produce particles
with carboxyl terminations and further conjugated to transferrin to target cell surface markers.
The hypothesis of this study was that the transferrin-coupled pSi particles would be able to cross the
BBB and, furthermore, bind to transferrin receptors found on the surface of tumour cells to deliver
the drug. Unlike many other studies involving the use of pSi as a drug delivery system, the focus of
this investigation was not to increase the solubility of a poorly aqueous soluble drug but to achieve
targeted drug delivery using functionalised pSi particles. The functionalisation of the silicon surface
increased the particles’ colloidal stability, as demonstrated by a decrease in hydrodynamic radius
measured by dynamic light scattering. Loading was determined to be 87.90 ± 2.16 µg/mg pSi particles,
with drug release dependent on the pH of the environment. The release of the drug was studied to
simulate endolysosomal and physiological conditions (pH 5 and 7.4, respectively). Stable hydrogen
bonds were formed between the pSi surface and doxorubicin in a neutral pH, limiting the drugs release.
Hydrogen bonds weakened in an acidic environment, leading to a greater drug release, with up to 90%
in 12 h. Furthermore, brain tumour tissue is known to have a lower pH than normal tissue; therefore,
a pH-dependent rate would be beneficial for improved drug release at the target site [123].
The successful confinement of crystalline and amorphous small drug molecules has led to research
into the confinement or adsorption of proteins to mesoporous substrates, an area of increasing promise
to the pharmaceutical industry [33,35,107,124].
The use of pSi as an aid in the crystallisation of proteins has also been investigated due to the
limited success of protein nucleation on other modified surfaces. The pSi was used as a substrate
on the basis that the pores would enable the confinement of protein molecules, which would lead to
nucleation and crystal growth. The average pore size of the material was between 5 and 10 nm with
a solution-loading method employed. The pSi induced the nucleation of five out of the six proteins
(lysozyme, trypsin, catalase, thaumatin, and phycobiliprotein) with a hydrodynamic radii ranging
from 2 to 5 nm, with crystals either growing on the silicon fragments or growing within the oil droplet
which suspended the silicon and protein solution, decreasing in size the further away they were from
the silicon fragment. This could have been due to nuclei diffusing away from the nucleation site or
nucleation taking place on smaller fragments of pSi. An explanation as to why concanavalin A, one of
the proteins, did not crystallise in the presence of the pSi substrate was not discussed. Further to this,
the influence of smaller pore sizes on crystallisation was investigated using other porous materials,
which did not prove successful. This has supported the hypothesis of the dependency of pore size
on the crystallisation of proteins. The crystallisation of proteins usually depends on the pH of the
system; however, using pSi as a nucleation surface removed this dependency with confinement of the
molecules, leading to localised supersaturation—hence, enabling crystallisation [33].
The loading of metformin into pSi for extended drug release has also been investigated. Metformin
is routinely administered in high and frequent doses, which can cause side effects within the
gastrointestinal tract. Attempts to increase the bioavailability of the drugs have been employed,
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including research into the encapsulation of metformin into chitosan-poly(lactide-co-glycolide)
nanoparticles only producing low encapsulation efficiency values [125]. The pSi offered the sustained
release needed due to a combination of morphological features and surface chemistry. The aim of the
work was to investigate the bonding between drug and carrier, an area which many other studies have
failed to address. The pSi was fabricated from electrochemical etching of silicon wafers with surface
passivation via thermal oxidation to promote the adsorption of the drug. The largest dimension of
the pore was determined to be 8 nm ± 2 nm. Due to the irregular shape of the pores, the average
pore diameter was not conclusive. Albeit, the pores were large enough to facilitate the free movement
of the drug into the pores and through the porous network. Interestingly, the authors analysed
the distribution of charge within the drug-loaded pSi and found that metformin was protonated in
media with a pH less than 2.8, monoprotonated between pH 2.8 and 11.5, and neutral above pH
11.5. The pH of the media also influenced the surface chemistry of the oxidised pSi, which therefore
influenced its drug-loading capacity. Particles displayed a positive surface charge at a pH of 2.2 or
lower and negative charge above that value. A zeta potential of less than 30 mV indicates particle
instability, which was determined to be at a pH less than 7. This provided an optimum pH of 7,
with the negatively charged surface of the pSi (Si-O−) favouring the loading of the positively charged
metformin molecules, with electrostatic forces enabling the interaction between the drug molecules and
the carriers’ surface (Figure 7). Overall, this study found thermally oxidised pSi to be advantageous as
a carrier of metformin, with prolonged release over a period of 26 h [126].
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The use of pSi as a carrier for fatty acid α-linolenic acid has also been reported [127]. The aim of
the study was to load compounds of nutritional benefit into a drug carrier in order to stimulate the
secretion of gut hormone glucagon-like peptide 1 (GLP-1). Nutrients such as fatty acids have been
known to aid the regulation of appetite and blood glucose levels, which is beneficial in the treatment
of obesity [128]. The pSi particles were first thermally hydrocarbonised to aid the loading of the
hydrophobic fatty acid and delay its release. Two drug-loading ratios were used within the study:
3% and 9.2%; however, 49.4% ± 6.29% and 25.7% ± 1.53% of the confined α-linolenic acid remained
unreleased, respectively. It was stated that the empty pSi did not stimulate to expression of GLP-1 from
the STC-1 cell line, but the fatty acid-loaded substrate increased GLP-1 secretion by 1.5% compared to
buffer alone. The detectable amount of α-linolenic acid was reduced with increased incubation time
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and acidity of the buffer, which may have been due to the accelerated oxidation of fatty acid in an acidic
environment [129]. However, the time in which fatty acids remain within the acidic environment of the
human stomach depends on many factors, including the type of food and how often it is consumed.
Microparticles of pSi loaded with GLP-1 were also reported to lower the blood glucose levels
after a single subcutaneous injection in mice, but none of the microparticles were able to prolong the
glucose-lowering effect, as compared to the GLP-1 solution [130]. In this study, the authors loaded
and released the GLP-1 peptide from negatively charged TOpSi and TCpSi microparticles and from
positively charged amine modified microparticles, designated as TOpSi-NH2-D (isolelectric point 8.8)
and TCpSi-NH2-D (isoelectric point 8.8), respectively. They found that the adsorption of GLP-1 onto
the pSi microparticles could be increased 3–4-fold by changing the pSi surface charge from negative
to positive, indicating that the positive surface charge of pSi promoted an electrostatic interaction
between the negatively charged peptide. The adsorption and desorption kinetics of the GLP-1 peptide
were also subject to study, where the authors concluded that, albeit electrostatic attraction between the
peptide and the pSi surface is relevant, at low concentrations, the hydrophobic interaction seems to
have a higher impact, even though the effect is less important for most hydrophilic nanoparticles [131].
Molecular modelling has been used to identify the intermolecular interactions that characterise
physicochemical factors, influencing the release of a drug from a dosage form [132]. Polkovnikova
and collaborators aimed to investigate the activation energy required for drug desorption from silicon
and silicon–dioxide surfaces. Desorption and dissolution of the drug from the surface was observed
when the van der Waals interaction energy reached zero. The activation energy was defined as the
difference between the average energy of the desorbed and adsorbed state in water. The change in
electronic energy was relative to the initial state, with the drug either in its ionised or unionised state
when adsorbed to the surface.
The unionised drug molecules were positioned flat on the surface of the silicon. Desorption of
the drug from the surface was said to occur in two stages: first, the separation of the polar part of the
molecule, followed by the separation of the hydrophobic phenyl radical, which was stated to have a
greater affinity for the silicon. Desorption energy profiles showed evidence of these two stages with a
two-stage energy increase. The ionised drug desorbed quicker than the unionised drug, also occurring
in two stages; firstly, the hydrophobic phenyl group attached to the SiH and SiOH groups of the silicon
surface and, then, the subsequent removal of the hydrophilic section of the drug. Bonding between the
drug and adsorbent surface was also investigated, with the hydrogen bond between the surface OH
group of the SiOH and the nitrogen atom of the drug breaking during desorption for both ionised and
unionised surfaces.
Estimations of the activation energies for the dissolution of the drug from the surface of the
adsorbent into water were calculated by using the difference between the electronic energies of the
system dissolved in water and the initial adsorbed state. The energy required for desorption of the
drug from the ionised SiO2 surface was overall the greatest, with desorption of the drug cation lower
than that of the drug in its unionised state (110.66 and 347.30 kJ/mol, respectively). Estimations of the
activation energy of drug desorption in aqueous solutions of different pH values were also investigated.
Drug desorption from the SiO2 surface at pH 6.8 and 7 showed the greatest statistical significance,
which is significant if dissolution was to occur in the large intestine.
The ability to load and release drug molecules trapped within its pores has led to discussions
over the possibility of employing pSi as a nanoscale delivery system but also raised concerns
about their toxicological profile in a biological setting [133]. Ever since pSi was first reported as a
bioactive material [48], many studies have been devoted to study its biocompatibility and biomedical
applications [134–140]. It has been reported that pSi biodegradation can be controlled by the overall
porosity, pore size, shape, surface, and bulk properties [141,142], which in turn can be modulated by
controlling the material fabrication parameters of the matrix [143,144]. For instance, pSi with a porosity
>70% dissolves in all the simulated body fluids (except gastric fluids), whereas pSi with a porosity
<70% is bioactive and slowly biodegradable [52]. The fact that pSi degrades mainly into monomeric
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silicic acid, Si(OH)4, the most natural form of Si in the environment and very important in human
physiology in protecting against the poisonous effects of aluminium [145], is an important feature that
contributes even further to the pSi apparent biocompatibility. It has been reported that the average
intake of Si is approximately 25–40 mg/day [146,147] and that Si is an essential nutrient for the human
body. Blood concentrations of Si(OH)4 have been found to be slightly above the typical values of
1 mg/L [145], and, most importantly, silicic acid does not accumulate within the human body and has
been shown to be absorbed readily by the gastrointestinal tract of humans and rapidly excreted via the
urinary pathway [148].
2. Summary
Mesoporous silicon has shown many advantages as a drug carrier due to its large loading
capacity, tuneable pore size, controlled drug release, and the ability to adapt the surface to suit the
drug to be loaded. Porous materials can influence the polymorphic form of the confined crystalline
state or stabilise the disordered amorphous state confined within them, which shows promise as
a way of improving the dissolution rate of poorly water-soluble drugs. Protein crystallisation has
also successfully utilised porous materials for heterogeneous nucleation, using porous silicon as a
templating surface.
From this review, we have been able to identify the issues faced by many researchers in their
investigations into the confinement of drug compounds in mesoporous materials; for example,
crystallisation on the surface of the porous substrate limiting the overall drug dissolution. A clear
understanding is needed of how external factors such as temperature and pH influence crystallisation, as
well as the pore structure and surface chemistry of the substrate, before translation to the pharmaceutical
industry. The nucleation of the crystalline state in porous silicon needs to be evaluated, including the
influence of pore diameter and pore volume, as well as the interactions between drug molecules and
the surface of the substrate. Neutron and synchrotron X-ray diffraction, as well as solid-state NMR, are
emerging as advanced characterisation techniques that are now beginning to be utilised to tackle this,
along with the conventional methods such as DSC and XRPD.
These fundamental issues need to be addressed continuously in order for research to turn to
the scale-up of these processes and make drug confinement in mesoporous materials feasible for
pharmaceutical development.
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